Angio-3 for treatment of retinal angiogenic diseases

Patent metadata

Field	Value
Publication number	US-11266710-B2
Application number	US-201816641978-A
Country	US
Kind code	B2
Filing date	Aug 31, 2018
Priority date	Aug 31, 2017
Publication date	Mar 8, 2022
Grant date	Mar 8, 2022

Abstract

This disclosure provides methods of a method of treating a retinal angiogenic in a subject comprising administering an effective amount of an Angio-3 peptide.

First claim

The invention claimed is:

1. A method of treating a retinal angiogenic disease in a subject comprising:
administering to the subject a pharmaceutically effective amount of a composition comprising a peptide consisting of the sequence Thr Pro His Thr His Gln Xaa Thr Pro Glu (SEQ ID NO:4),
wherein the composition is administered to the subject orally, by intravenous injection, or by intravitreal injection and wherein administration treats the retinal angiogenic disease in the subject.

2. The method of claim 1 , wherein the composition comprises 2 to 50 mg/kg body weight (Bwt) and is administered by intravenous injection.

3. The method of claim 1 , wherein the composition comprises 0.1 μg/kg to 2 mg/kg Bwt and is administered by intravitreal injection.

4. The method of claim 1 , wherein the composition comprises 2 to 10 mg/kg Bwt and is administered orally.

5. The method of claim 1 , wherein the composition is administered via either intravenous (IV) or intravitreal (IVT) route at least once every 4 to 10 weeks.

6. The method of claim 1 , wherein the composition is administered orally at least once daily for 1 to 2 weeks at intervals of 6 months.

7. The method of claim 1 , wherein subject is not responsive to anti-vascular endothelial growth factor (VEGF) therapy.

8. The method of claim 7 , wherein the anti-VEGF therapy is an anti-VEGF antibody.

9. The method of claim 1 , wherein the subject has age-related macular degeneration, retinopathy, or vascular occlusion.

10. The method of claim 1 , wherein the subject has diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, or corneal neovascularization.

11. The method of claim 1 , wherein the subject is a human.

Assignees

• Singapore Health Serv Pte Ltd
• Nat Univ Singapore

Inventors

• Belkin Michael
• Barathi Veluchamy Amutha
• Lakshminarayanan Rajamani
• Kini R Manjunatha
• Ruowen Ge
• Wong Tien Yin
• Cheung Gemmy Chui Ming

Classifications

• A61K38/08 Primary

  Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61P27/02 Primary

  Ophthalmic agents · CPC title